Q2 2024 EPS Estimates for Envista Holdings Co. Decreased by Analyst (NYSE:NVST)

Envista Holdings Co. (NYSE:NVST) – Equities researchers at William Blair cut their Q2 2024 earnings per share (EPS) estimates for shares of Envista in a report issued on Wednesday, May 1st. William Blair analyst B. Vazquez now anticipates that the company will post earnings of $0.32 per share for the quarter, down from their previous forecast of $0.34. William Blair has a “Market Perform” rating on the stock. The consensus estimate for Envista’s current full-year earnings is $1.38 per share. William Blair also issued estimates for Envista’s FY2024 earnings at $1.35 EPS, Q1 2025 earnings at $0.32 EPS, Q2 2025 earnings at $0.34 EPS, Q3 2025 earnings at $0.37 EPS, Q4 2025 earnings at $0.42 EPS and FY2025 earnings at $1.46 EPS.

NVST has been the topic of several other reports. Robert W. Baird lowered their price target on Envista from $22.00 to $19.00 and set a “neutral” rating on the stock in a research note on Thursday. Needham & Company LLC restated a “hold” rating on shares of Envista in a research report on Thursday. SVB Leerink assumed coverage on Envista in a research report on Monday, February 26th. They issued an “underperform” rating and a $19.00 target price for the company. Morgan Stanley downgraded shares of Envista from an “overweight” rating to an “equal weight” rating and decreased their price target for the stock from $33.00 to $21.00 in a research note on Friday, April 26th. Finally, TheStreet downgraded shares of Envista from a “c” rating to a “d+” rating in a report on Wednesday, February 7th. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, Envista presently has a consensus rating of “Hold” and an average target price of $25.86.

Envista Stock Performance

NYSE:NVST opened at $19.00 on Friday. The company has a debt-to-equity ratio of 0.34, a quick ratio of 1.90 and a current ratio of 2.27. The firm’s 50-day moving average is $20.66 and its 200-day moving average is $22.53. Envista has a 52-week low of $18.09 and a 52-week high of $36.74. The company has a market cap of $3.27 billion, a price-to-earnings ratio of -26.40, a PEG ratio of 3.83 and a beta of 1.35.

Envista (NYSE:NVST) last released its earnings results on Wednesday, May 1st. The company reported $0.26 EPS for the quarter, missing the consensus estimate of $0.31 by ($0.05). The company had revenue of $623.60 million for the quarter, compared to analyst estimates of $634.85 million. Envista had a negative net margin of 4.70% and a positive return on equity of 5.84%. Envista’s revenue for the quarter was down .6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.38 earnings per share.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of NVST. Headinvest LLC bought a new position in shares of Envista in the third quarter valued at about $28,000. Fifth Third Bancorp lifted its position in shares of Envista by 98.1% during the fourth quarter. Fifth Third Bancorp now owns 1,254 shares of the company’s stock worth $30,000 after purchasing an additional 621 shares in the last quarter. Itau Unibanco Holding S.A. acquired a new position in shares of Envista during the third quarter worth approximately $47,000. Covestor Ltd grew its stake in shares of Envista by 33.9% during the third quarter. Covestor Ltd now owns 2,462 shares of the company’s stock valued at $69,000 after purchasing an additional 624 shares during the last quarter. Finally, Signaturefd LLC increased its holdings in shares of Envista by 1,297.9% in the fourth quarter. Signaturefd LLC now owns 2,614 shares of the company’s stock valued at $63,000 after purchasing an additional 2,427 shares in the last quarter.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.